Telehealth Monitoring in Inflammatory Bowel Disease: Effects on Medication Compliance, Self-Efficacy, and Quality of Life
The Effect of Telehealth Monitoring on Medication Compliance, Self-Efficacy and Quality of Life in Patients With İnflammatory Bowel Disease
Istanbul University - Cerrahpasa
120 participants
Apr 20, 2024
INTERVENTIONAL
Conditions
Summary
This randomized controlled trial aims to evaluate the effect of nurse-led telehealth monitoring on medication adherence, self-efficacy, and quality of life in individuals with inflammatory bowel disease (IBD). The study will be conducted at the IBD Outpatient Clinic of Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty. Participants will be randomly assigned to either an intervention group receiving a 3-month structured telehealth program (including education, counseling, phone calls, and reminders) or a control group receiving only standard care and an educational booklet. Outcomes will be assessed at baseline and after 12 weeks.
Eligibility
Inclusion Criteria9
- Individuals aged 18 years or older
- Individuals aged 18 years or older
- Able to read and write in Turkish
- Diagnosed with inflammatory bowel disease (IBD) for at least 6 months
- In clinical remission (Harvey-Bradshaw Index score \< 5 or Simple Clinical Colitis Activity Index score \< 3)
- Able to use a smartphone
- Have access to an online messaging application (e.g., WhatsApp) and a valid e-mail address
- Capable of downloading and using a mobile or computer-based video conferencing application (e.g., Zoom)
- Willing to participate in the study voluntarily
Exclusion Criteria5
- Diagnosed with any psychiatric or cognitive disorder
- Having any condition that impairs communication
- Pregnant women
- Patients receiving infusion-based treatment
- Having an advanced chronic disease
Interventions
Participants in the intervention group will be included in a structured telehealth monitoring program led by a nurse for 12 weeks.
Participants in the control group will only receive standard care. No additional interventions will be implemented during the 12-week period.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06971627